Anti-Diabetes Drugs - Germany | Statista Market Forecast

in Germany, as a country, plays a significant role in the Anti-Diabetes Drugs market.
The projected revenue for this market in Germany is estimated to reach US$2.37bn by 2024.
This represents a considerable growth potential for the country.
Looking ahead, the market is expected to continue expanding at a compound annual growth rate (CAGR) of 7.17% between 2024 and 2029.
By 2029, the market volume in Germany is predicted to reach US$3.35bn.
In comparison to other countries, United States is anticipated to generate the highest revenue in the Anti-Diabetes Drugs market, with an estimated US$37.84bn in 2024.
This illustrates the dominant position of the United States in this market.
Germany has seen a surge in the demand for innovative anti-diabetes drugs, driven by the country's strong healthcare infrastructure and focus on research and development.

Definition:
The Anti-Diabetes Drugs market covers drugs to treat the metabolism disorder diabetes mellitus. It includes insulin and non-insulinotropic drugs such as glucagen-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. While patients with type 1 diabetes require lifelong insulin therapy, type 2 diabetes can also be treated with medication.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novo Nordisk, Eli Lilly, Sanofi, Merck & Co

Drugs to treat diabetes mellitus (oral intake and injections)
Insulin
Non-insulinotropic anti-diabetic drugs

Drugs to treat other metabolic disorders or other autoimmune diseases
Lipid-lowering agents
Drugs to treat hypertension
Diagnostics
Devices such as continuous glucose monitors

The Anti-Diabetes Drugs market in Germany has been experiencing significant growth in recent years.

Customer preferences: There has been a growing demand for anti-diabetes drugs in Germany due to the increasing prevalence of diabetes in the country. The aging population and unhealthy lifestyle choices have contributed to the rise in diabetes cases. As a result, customers are looking for effective and affordable treatments to manage their condition.

Trends in the market: One of the major trends in the Anti-Diabetes Drugs market in Germany is the shift towards personalized medicine. More and more patients are seeking tailored treatment options that are specific to their individual needs. This has led to the development of new drugs that target specific types of diabetes, such as type 2 diabetes. Additionally, there has been a trend towards the use of combination therapies, where multiple drugs are used simultaneously to achieve better results.

Local special circumstances: Germany has a well-established healthcare system that provides comprehensive coverage for anti-diabetes drugs. This has made it easier for patients to access the drugs they need to manage their condition. Additionally, there is a strong focus on research and development in the country, which has led to the development of new and innovative drugs.

Underlying macroeconomic factors: The German economy has been performing well in recent years, which has led to an increase in disposable income for many consumers. This has made it easier for patients to afford the anti-diabetes drugs they need. Additionally, there is a growing awareness of the importance of managing diabetes, which has led to increased demand for anti-diabetes drugs. Finally, the aging population in Germany has contributed to the growth of the Anti-Diabetes Drugs market, as older individuals are more likely to develop diabetes and require treatment.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

In 2021, diabetes mellitus caused an estimated 1.62 million deaths worldwide, making it the eighth leading cause of death. Furthermore, it is estimated that 537 million people are currently living with diabetes around the world, with this number projected to rise to some 783 million by the year 2045. Diabetes describes a group of metabolic diseases which cause high blood sugar levels. There are three types of diabetes: type 1 diabetes, type 2 diabetes, and gestational diabetes. However, the majority of diabetes cases are type 2, with an estimated 90 to 95 percent of diabetes cases in the United States type 2. Risk factors for type 2 diabetes include being overweight, being physically inactive, being 45 and older, and having prediabetes.